Serum Institute of India Pvt. Ltd (SIIPL) and the University of Oxford have entered into a Technology Licence Agreement facilitated by Oxford University Innovation to combat Men-B disease. This partnership aims to produce a chimeric protein-based vaccine offering improved protection against Neisseria meningitidis, addressing the limitations of current Men-B vaccines in terms of efficacy, safety, and coverage.

Simon Warner, Head of Licensing & Ventures – Life Sciences at Oxford University Innovation, commented, "Our collaboration with Serum Institute of India on the Men-B vaccine is a testament to Oxford's dedication to vaccine innovation. Oxford's ongoing efforts in vaccine development aim to safeguard millions of lives through effective academic licensing and impactful commercial partnerships."

Invasive meningococcal disease (IMD) remains a significant global health challenge, affecting millions of children worldwide. The disease is caused by six serogroups (Men-A, -B, -C, -W, -Y, and -X) of the bacterium. After five years of collaborative research, SIIPL and the Oxford team, led by Professor Christoph Tang at the Sir William Dunn School of Pathology, have developed a quadrivalent vaccine comprising four chimeric proteins targeting Men-B. Preliminary results expected later this year suggest that the Oxford-SIIPL protein-based vaccine offers advancements in safety, efficacy, and coverage compared to existing licensed vaccines.

Building on the success of MenAfriVac® in eradicating Men-A disease from sub-Saharan Africa, SIIPL's groundbreaking MenFive® (Meningococcal ACYWX Polysaccharide Conjugate Vaccine) is also under development. Discussions are in progress to deploy MenFive® as a proactive measure against meningococcal meningitis, aligning with the World Health Organization's goal to eliminate meningitis by 2030.

Adar Poonawalla, CEO of Serum Institute of India Pvt. Ltd (SIIPL), stated, "This partnership signifies a significant advancement in our battle against meningitis, ensuring that life-saving protection is accessible to those in need."

This collaboration highlights a shared commitment to global health and emphasizes the importance of accessible vaccines. Through longstanding partnerships and ongoing initiatives, both institutions are dedicated to making a positive impact and reaching communities in need worldwide, contributing to a healthier, safer future for all.